Not yet recruitingPhase 2NCT07146880
Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
Studying Brugada syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Taiwan University Hospital
- Principal Investigator
- Joseph Wu, MD, PhdStanford University
- Intervention
- Empagliflozin (EMPA)(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- National Taiwan University Hospital, Taipei, Taiwan, Taiwan
Collaborators
Stanford University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07146880 on ClinicalTrials.govOther trials for Brugada syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06647927GenLab: Unveiling the Genetic Landscape of Brugada Syndrome: Novel Biomarker Discovery for Precise DiagnosisIRCCS Policlinico S. Donato
- RECRUITINGNCT06988189Unmasking Concealed Arrhythmia SyndromesImperial College London
- RECRUITINGNANCT05643209Brugada Syndrome Substrate Characterization and AblationMaria Cecilia Hospital
- RECRUITINGNCT05521451Clinical Cohort Study - TRUSTUniversitätsklinikum Hamburg-Eppendorf
- ACTIVE NOT RECRUITINGNANCT05685134Epicardial Radiofrequency Catheter Ablation in Patients With Brugada Syndrome: a Randomized, Sham-controlled, Masked Clinical TrialUniversity of Sao Paulo General Hospital
- ACTIVE NOT RECRUITINGNCT04257994Distribution of Cell-cell Junction Proteins in Arrhythmic DisordersSt. George's Hospital, London
- ENROLLING BY INVITATIONNCT02413450Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac ArrhythmiasJohns Hopkins University
- RECRUITINGNCT05283759UZ Brussel HRMC Registry of Brugada SyndromeUniversitair Ziekenhuis Brussel